Journal article
European guidelines on managing adverse effects of medication for ADHD
J Graham, T Banaschewski, J Buitelaar, D Coghill, M Danckaerts, RW Dittmann, M Doepfner, R Hamilton, C Hollis, M Holtmann, M Hulpke-Wette, M Lecendreux, E Rosenthal, A Rothenberger, P Santosh, J Sergeant, E Simonoff, EJS Sonuga-Barke, ICK Wong, A Zuddas Show all
European Child and Adolescent Psychiatry: official journal of the European Society for Child and Adolescent Psychiatry | SPRINGER | Published : 2011
Abstract
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
Meeting costs of the Guidelines was supported by: Lilly, Medice, Novartis, UCB, Shire. No fees were paid to participants.